Pharmaxis

Company description

Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases.Our first product, Aridol, is now registered for sale in the United States, Europe, Australia and South East Asia. Aridol is designed to assist in the management of both asthma and chronic obstructive pulmonary disease.
Our second product, Bronchitol, an Australian discovered and developed product which was approved for marketing in Australia in February 2011. In October 2011 Bronchitol received a positive opinion by a European regulatory committee, clearing the way for its marketing in 29 countries in Europe.
We are committed to bringing our therapeutic advances for respiratory and immune diseases to patients throughout the world, and to building an internationally successful pharmaceutical business: one that’s built to last.

Products and services

Products

Pharmaxis has a strong suite of products in development, primarily focused on treating respiratory diseases. The target disease states are under-treated and many have broad patient bases.

Aridol

Overview
Pharmaxis’ first commercial product, the innovative Aridol lung function test, is designed to assist physicians in the overall assessment of asthma by identifying and measuring airway hyperresponsiveness.

By having patients inhale Aridol via a simple hand-held device, doctors can determine the severity of a patient’s inflammation and prescribe the right amount of medication to bring it under control. The Aridol challenge test potentially prevents inappropriate treatment and may help patients better comply with their therapies.

Aridol is approved for sale in Australia, major European countries, South Korea and the United States. Bronchitol
Overview
Pharmaxis’ key product in development, Bronchitol, is a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions.
Pharmaxis is developing Bronchitol for diseases including bronchiectasis, cystic fibrosis and chronic bronchitis. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Clinical studies have shown Bronchitol to be effective and well tolerated, to improve quality of life and mucus flow in people with cystic fibrosis and bronchiectasis.
Bronchitol is an Australian discovered and developed product which was approved for marketing in Australia in February 2011. In October 2011 Bronchitol received a positive opinion by a European regulatory committee, clearing the way for its marketing in 29 countries in Europe.